Published in Clin Cancer Res on September 15, 2008
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods (2012) 1.46
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood (2013) 1.44
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol (2013) 1.17
Signaling pathways involved in MDSC regulation. Biochim Biophys Acta (2014) 1.12
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer (2010) 1.01
Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol (2010) 0.97
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest (2010) 0.92
Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy (2011) 0.91
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy (2011) 0.91
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther (2010) 0.91
Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells. PLoS One (2013) 0.91
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90
Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc (2010) 0.90
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 0.88
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer (2014) 0.86
Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 0.85
Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer (2011) 0.84
Molecular pathways: myeloid complicity in cancer. Clin Cancer Res (2014) 0.84
Myeloid-derived cells are key targets of tumor immunotherapy. Oncoimmunology (2014) 0.82
Stromal-dependent tumor promotion by MIF family members. Cell Signal (2014) 0.81
Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma. Clin Transl Med (2014) 0.80
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. Br J Cancer (2014) 0.79
Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2016) 0.77
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77
Advances in cellular therapy for the treatment of thyroid cancer. J Oncol (2010) 0.76
The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood. Clin Exp Immunol (2016) 0.76
Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76
Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. Oncol Lett (2016) 0.75
Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. Oncoimmunology (2015) 0.75
Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release (2016) 0.75
Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology (2015) 0.75
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A (2010) 6.72
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Cell death independent of caspases: a review. Clin Cancer Res (2005) 3.85
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44
Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet (2005) 2.36
Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs (2003) 2.35
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol (2004) 1.93
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp (2010) 1.83
Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res (2008) 1.81
MRP6 (ABCC6) detection in normal human tissues and tumors. Lab Invest (2002) 1.79
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood (2011) 1.76
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol (2012) 1.68
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer (2006) 1.67
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol (2002) 1.64
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 1.60
Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol (2007) 1.60
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57
Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol (2013) 1.56
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood (2010) 1.56
Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A (2004) 1.56
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther (2002) 1.52
Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat (2011) 1.51
Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proc Natl Acad Sci U S A (2012) 1.50
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49
EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol (2007) 1.48
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45
Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44
Evidence for subcomplexes in the Fanconi anemia pathway. Blood (2006) 1.43
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40
Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp (2011) 1.40
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene (2003) 1.39
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer (2007) 1.38
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol (2008) 1.37